The Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in companion diagnostics partnering deals Companion diagnostics partnering agreement structure Companion diagnostics partnering contract documents Top companion diagnostics deals by value Most active companion diagnostics dealmakers
The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.
The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 500 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.
Key benefits Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 report provides the reader with the following key benefits: In-depth understanding of Companion Diagnostics deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies Identify most active Companion Diagnostics dealmakers since 2010 Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.
Companion Diagnostics Partnering Terms and Agreements includes: Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010 Analysis of Companion Diagnostics deal structure Access to headline, upfront, milestone and royalty data Access to Companion Diagnostics contract documents Leading Companion Diagnostics deals by value since 2010 Most active Companion Diagnostics dealmakers since 2010
In Global Companion Diagnostics Partnering Terms and Agreements 2010-2021, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 500 Companion Diagnostics deals.
Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
2021 Germany Diagnostics Market for 500 Tests This new report provides granular analysis of the diagnostic testing market, including volume and sales forecasts by test for the following market segments: - Blood Banking - Cancer - Chemistry - Coagulation - Drugs of Abuse - Endocrine - Hematology...
2021 HIV/AIDS Molecular Diagnostics Market: USA, Europe, Japan--Supplier Shares, Test Volume and Sales Forecasts by Country and Market Segment--Hospitals, Blood Banks, Commercial and Public Health Labs, POC Locations
This 7-country report presents test volumes, sale forecasts and supplier shares for the US, Europe...
The veterinary diagnostics market is expected to reach USD 3.9 billion by 2026 from an estimated USD 2.5 billion in 2021, at a CAGR of 9.4%. Market growth can largely be attributed to the growth in the companion animal population, increasing incidence of transboundary and zoonotic diseases, rising demand for animal-derived food products, rising...
Global Endoscopy Capsule Market, By Product Type (Small Bowel, Esophageal, Colon), By Accessories (Wireless Capsule v/s Workstation and Receiver), By Application (Obscure Gastrointestinal Bleeding, Crohn’s Disease, Small Intestine Tumor, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By Company, By Region,...
The global infectious disease diagnostics market size is projected to reach USD 39.8billion by 2026 from USD 28.1billion in 2021, at a CAGR of 7.2% during the forecast period. Market growth is driven by factors such as global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift...
Asia-Pacific Nuclear Medicine Market by Type (Diagnostics, Therapeutics, and Biochemistry Research), Modality (SPECT, PET, Beta emitters, Alpha Emitters, Brachytherapy, and Others), Application (Oncology, Cardiology, Thyroid, Neurology, ad Others) and End User (Hospitals & Diagnostic Centers and Research Institutes): Regional Opportunity...
120 pages •
By Infiniti Research Limited
• May 2021
Global Automotive On-board Diagnostics (OBD) Market 2021-2025 The analyst has been monitoring the automotive on-board diagnostics (OBD) market and it is poised to grow by $ 27.63 billion during 2021-2025, progressing at a CAGR of over 17% during the forecast period. Our report on automotive on-board diagnostics (OBD) market...
The Asia Pacific irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 739.70 million by 2028 from US$ 448.31 million in 2020; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028. The growth of the market is determined due to some of the key driving factors, such as increasing prevalence of irritable bowel syndrome...
120 pages •
By Infiniti Research Limited
• Apr 2021
Global Animal Health Diagnostics Market 2021-2025 The analyst has been monitoring the animal health diagnostics market and it is poised to grow by USD 1.78 billion during 2021-2025, progressing at a CAGR of almost 10% during the forecast period. Our report on the animal health diagnostics market provides a holistic analysis,...
The multimodal image fusion software market was valued at US$ 298.29 million in 2020 and is projected to reach US$ 552.30 million by 2028; it is expected to grow at a CAGR of 8.1% during 2021–2028. Increasing government and private spending on healthcare infrastructure is a major factor driving the multimodal image fusion software market....
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.